Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma
Abstract While immunotherapeutic targeting of cell surface proteins is an increasingly effective cancer therapy, identification of new surface proteins, particularly those with biological importance, is critical. Here, we uncover delta-like non-canonical Notch ligand 1 (DLK1) as a cell surface prote...
Saved in:
| Main Authors: | Nai-Yun Sun, Suresh Kumar, Yoo Sun Kim, Diana Varghese, Arnulfo Mendoza, Rosa Nguyen, Reona Okada, Karlyne Reilly, Brigitte Widemann, Yves Pommier, Fathi Elloumi, Anjali Dhall, Daiki Taniyama, Mayank Patel, Etan Aber, Cristina F. Contreras, Rosandra N. Kaplan, Katja Kiseljak-Vassiliades, Margaret E. Wierman, Dan Martinez, Jennifer Pogoriler, Amber K. Hamilton, Sharon J. Diskin, John M. Maris, Robert W. Robey, Michael M. Gottesman, Jaydira Del Rivero, Nitin Roper |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-60649-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma
by: Katia Mariniello, et al.
Published: (2025-06-01) -
Molecular mechanism of Activin receptor inhibition by DLK1
by: Daniel Antfolk, et al.
Published: (2025-07-01) -
Dlk1 is necessary for proper skeletal muscle development and regeneration.
by: Jolena N Waddell, et al.
Published: (2010-11-01) -
The evolution of the DLK1-DIO3 imprinted domain in mammals.
by: Carol A Edwards, et al.
Published: (2008-06-01) -
DLK1 and DLK2, two non-canonical ligands of NOTCH receptors, differentially modulate the osteogenic differentiation of mesenchymal C3H10T1/2 cells
by: María-Milagros Rodríguez-Cano, et al.
Published: (2024-10-01)